JavaScript is disabled. Please enable to continue!

Mobile search icon
Pharma Newsletters >> Eurofins BioPharma Services Newsletter 39 - December 2024 >> Eurofins Central Laboratory announces the finalisation of its acquisition of assets for Clinical Trial Pathology Services from DCL Pathology LLC

Eurofins Central Laboratory announces the finalisation of its acquisition of assets for Clinical Trial Pathology Services from DCL Pathology LLC

Sidebar Image

Sandra Hageman, Senior Director Marketing, Eurofins Clinical Trial Solutions Network of Companies, Sandra.Hageman@bcl.eurofins.com

Pathology SampleFounded in 1984, DCL Pathology is a College of American Pathologists (CAP) accredited laboratory and is internationally recognised as expert providers of clinical trial pathology services, with specific expertise in women’s health, urology, and oncology studies. The Pathology facility operates in Carmel, Indianapolis, US, and is joining the collective network of Eurofins Clinical Trial Solutions facilities to enhance its service offerings, including providing histology, cytology, pathology, and molecular testing services such as DNA, RNA and Protein quantification, qPCR, and Next Generation Sequencing.

Their technical service expertise is uniquely positioned for serving pharma/biotech clients, as well as clinical CROs in the global clinical trial space and will complement the Eurofins Clinical Trial Solutions’ extensive portfolio of central laboratory, bioanalytical, biomarker, and molecular genomic testing services in support of clinical trials. This acquisition has resulted in Eurofins Clinical Trial Solutions being able to broaden its service offerings to clients, especially in the Oncology and Vaccine Development areas. For more information visit: www.eurofins.com/biopharma-services/clinical-trial-solutions/